

## **EUROPEAN COMMISSION**

**HEALTH & CONSUMERS DIRECTORATE-GENERAL** 

Public Health and Risk Assessment Risk assessment

## **Scientific Committee on Consumer Safety**

# $11^{th}$ meeting of the WG 'Cosmetic Ingredients' – 1 June 2010

### **Minutes**

### 1. WELCOME AND APOLOGIES

The Chair of the working group (WG) welcomed the participants and communicated the apologies received.

### 2. ADOPTION OF THE AGENDA

The draft agenda was adopted (annex 1).

## 3. DECLARATION OF INTEREST ON MATTERS OF THE AGENDA

No member declared any interest that could prevent him/her from participating in the discussion of the items on the agenda.

## 4. DRAFT OPINIONS

Draft opinions on the following substances were discussed by the Working Group:

- 4.1. Cyclomethicone (D4)
- 4.2. CMR borates
- 4.3 CMR perborates
- 4.4. Diethylene glycol monoethyl ether (DEGEE)
- 4.5. Erythrosine
- 4.6. P63, Quaternium-15
- 4.7. P82, Parabens
- 4.8. Dihydroxyacetone (DHA)
- 4.9. S74, Polysilicone-15

The draft opinions on Cyclomethicone (D4), borates, perborates, DEGEE, Erythrosine, P82 (parabens) and on DHA were addressed to the plenary meeting of 22 June for formal adoption.

\_\_\_\_\_

## 5. PROGRESS REPORTS

The members of the WG were updated on the progress of the following mandates, for which no draft opinion has been received yet:

- 5.1. P32, Triclosan updated mandate
- 5.2. Ethyl lauryl arginate (P95)
- 5.3. P81, Zinc pyrithione
- 5.4. Arbutin / desoxyarbutin
- 5.5. Chloromethane
- 5.6 Bis(butylbenzoate)diaminotriazine (S85)
- 5.7. Chloroacetamide

## 6. NEW REQUESTS

- 6.1 Trisodium nitrilotriacetate/N-methyl-2-pyrrolidone
- 6.2 Objection on the opinion on Kojic acid (SCCP/1182/08)

## 7. COMMENTS ON PREVIOUSLY ADOPTED OPINIONS

- 7.1. P56, MCI/MI
- 7.2 Vitamin K1
- 7.3 Melatonin

## 8. ANY OTHER BUSINESS

The next meeting will take place on 7 July 2010.

Annex 1: draft agenda

### Annex 1

## Scientific Committee on Consumer Safety (SCCS) WG on Cosmetic Ingredients

#### 1 June 2010

#### DRAFT AGENDA

- 1. Welcome and apologies
- 2. Adoption of the agenda
- 3. Declaration of interest on matters on the agenda
- 4. Draft opinions on:
- 4.1. Cyclomethicone (D4)
- 4.2. CMR borates
- 4.3 CMR perborates
- 4.4. DEGEE
- 4.5. Erythrosine
- 4.6. P63, Quaternium-15
- 4.7. P82, Parabens
- 4.8. DHA
- 4.9. S74, Polysilicone-15

## 5. Progress reports

- 5.1. P32, Triclosan updated mandate
- 5.2. Ethyl lauryl arginate (P95)
- 5.3. P81, Zinc pyrithione
- 5.4. Arbutin / desoxyarbutin
- 5.5. Chloromethane
- 5.6 Bis(butylbenzoate)diaminotriazine (S85)
- 5.7. Chloroacetamide
- **6.** New requests (discussion on rapporteur and/or next steps)
- 6.1 Trisodium nitrilotriacetate/N-methyl-2-pyrrolidone
- 6.2 Objection on opinion SCCP/1182/08 Kojic acid
- 7. Comments on previously adopted opinions
- 7.1. P56, MCI/MI
- 7.2 Vitamin K1
- 7.3 Melatonin

# 8. Any Other Business